After $1 Million Drug Flop, UniQure Seeks Gene-Therapy Revival – Bloomberg
|
After $1 Million Drug Flop, UniQure Seeks Gene–Therapy Revival
Bloomberg UniQure is also developing experimental gene therapies for Huntington's disease and collaborating with Bristol-Myers Squibb Co., which owns about 7.5 percent of the shares, on treatments for cardiovascular illnesses. The company would consider new … |
